Trial Enrollment Information

Delcath has commenced a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS for the treatment of primary liver cancer (hepatocellular carcinoma or HCC). We are also initiating a cohort within the global phase 2 clinical trial to evaluate patients with intrahepatic cholangiocarcinoma (ICC). We are also advancing plans to conduct a global Phase 3 trial in ocular melanoma that has metastasized to the liver.

Learn More >>>


Trial Enrollment

Completed Clinical Trials

Learn about the outcomes of our most recently completed clinical trials.

Learn More


Disclaimer:

Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.